## Christopher Adlbrecht

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8973248/publications.pdf

Version: 2024-02-01

49 papers

3,017 citations

279487 23 h-index 223531 46 g-index

52 all docs 52 docs citations

times ranked

52

4404 citing authors

#	Article	IF	CITATIONS
1	The impact of subclinical congestion on the outcome of patients undergoing transcatheter aortic valve implantation. European Journal of Clinical Investigation, 2020, 50, e13251.	1.7	10
2	Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors*. Critical Care Medicine, 2020, 48, 167-175.	0.4	16
3	Fitness-Tracker Assisted Frailty-Assessment Before Transcatheter Aortic Valve Implantation: Proof-of-Concept Study. JMIR MHealth and UHealth, 2020, 8, e19227.	1.8	11
4	Intravenous iron therapy for patients with heart failure: expanding body of evidence. ESC Heart Failure, 2019, 6, 581-583.	1.4	6
5	Non-occlusive mesenteric ischaemia in out of hospital cardiac arrest survivors. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 450-458.	0.4	13
6	GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. Clinical Chemistry, 2016, 62, 1612-1620.	1.5	26
7	Outcome of conservative management vs. assist device implantation in patients with advanced refractory heart failure. European Journal of Clinical Investigation, 2016, 46, 34-41.	1.7	6
8	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2016, 134, 1314-1324.	1.6	127
9	Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure ( <scp>STICH</scp> ) trial. European Journal of Heart Failure, 2015, 17, 725-734.	2.9	19
10	Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size. Circulation Research, 2015, 116, 1182-1192.	2.0	373
11	Pro-oxidant HDL predicts poor outcome in patients with ST-elevation acute coronary syndrome. Thrombosis and Haemostasis, 2015, 114, 133-138.	1.8	11
12	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart, 2015, 101, 1874-1880.	1.2	181
13	Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 176-182.	1.8	10
14	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. International Journal of Cardiology, 2014, 174, 90-95.	0.8	2
15	Effects of endothelin A receptor blockade in patients with ST-elevation acute coronary syndrome — A rhythmologic substudy. Life Sciences, 2014, 118, 430-434.	2.0	4
16	Prognostic value of culprit site neutrophils in acute coronary syndrome. European Journal of Clinical Investigation, 2014, 44, 257-265.	1.7	28
17	Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure. Journal of Heart and Lung Transplantation, 2013, 32, 533-538.	0.3	10
18	Prognostic value of induction of atrial fibrillation before and after pulmonary vein isolation. International Journal of Cardiology, 2013, 164, 212-216.	0.8	8

#	Article	IF	CITATIONS
19	PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dlabetic patients) Tj ETQq1 1 0.78 1365-1372.	34314 rgB <sup>-</sup> 1.2	「/Overloc <mark>k</mark> ] 253
20	Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. European Heart Journal, 2013, 34, 844-852.	1.0	150
21	Research update for articles published in <scp>EJCI</scp> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	1.7	2
22	NT-proBNP as a means of triage for the risk of hospitalisation in primary care. European Journal of Preventive Cardiology, 2012, 19, 55-61.	0.8	10
23	Proteomic profiling of acute coronary thrombosis reveals a local decrease in pigment epithelium-derived factor in acute myocardial infarction. Clinical Science, 2012, 123, 111-119.	1.8	9
24	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
25	Inorganic phosphate and FGFâ€23 predict outcome in stable systolic heart failure. European Journal of Clinical Investigation, 2012, 42, 649-656.	1.7	64
26	Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention, 2012, 7, 1386-1395.	1.4	18
27	The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): Influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. American Heart Journal, 2011, 161, 611-621.	1.2	36
28	Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. European Journal of Clinical Investigation, 2011, 41, 315-322.	1.7	43
29	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	1.7	0
30	Target vessel reopening by guidewire insertion in ST-elevation myocardial infarction is a predictor of final TIMI flow and survival. Thrombosis and Haemostasis, 2011, 105, 52-58.	1.8	3
31	Electrical optimization of cardiac resynchronization in chronic heart failure is associated with improved clinical longâ€term outcome. European Journal of Clinical Investigation, 2010, 40, 678-684.	1.7	14
32	Prognostic Value of Emerging Neurohormones in Chronic Heart Failure during Optimization of Heart Failure–Specific Therapy. Clinical Chemistry, 2010, 56, 121-126.	1.5	50
33	Treatment of a recurrent atrial tachycardia by isolation of the right inferior pulmonary vein using a multi-electrode duty cycled ablation catheter. Europace, 2010, 12, 1788-1789.	0.7	0
34	Quality of Life after Late Invasive Therapy for Occluded Arteries. New England Journal of Medicine, 2009, 360, 774-783.	13.9	34
35	Prognostic value of plasma midregional proâ€adrenomedullin and Câ€terminalâ€proâ€endothelinâ€1 in chronic heart failure outpatients. European Journal of Heart Failure, 2009, 11, 361-366.	2.9	78
36	Levels of sCD40, sCD40L, TNFα, and TNF-RI in the Culprit Coronary Artery During Myocardial Infarction. Laboratory Medicine, 2009, 40, 660-664.	0.8	1

#	Article	IF	Citations
37	Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. European Journal of Clinical Investigation, 2009, 39, 1073-1081.	1.7	15
38	Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal, 2009, 157, 837-844.e3.	1.2	33
39	Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thrombosis and Haemostasis, 2009, 102, 564-572.	1.8	103
40	Role for Staphylococci in Misguided Thrombus Resolution of Chronic Thromboembolic Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 678-684.	1.1	100
41	Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. European Heart Journal, 2008, 29, 2343-2350.	1.0	113
42	Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2007, 115, 2153-2158.	1.6	263
43	Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thrombosis and Haemostasis, 2007, 97, 642-649.	1.8	32
44	Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2005, 93, 512-516.	1.8	253
45	Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2005, 128, 2599-2603.	0.4	129
46	Title is missing!. Molecular and Cellular Biochemistry, 2003, 249, 39-43.	1.4	2
47	High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2003, 90, 372-376.	1.8	221
48	Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood, 2002, 99, 2794-2800.	0.6	126
49	Inhibition of IL- $1\hat{l}^2$ convertase is associated with decrease of in-stent neointima after coronary stenting in pigs. Journal of Molecular and Cellular Cardiology, 2002, 34, A27.	0.9	0